Ad-IL-24对MG-63人骨肉瘤细胞抑癌效应的体内外实验

本研究旨在分析腺病毒携带的IL-24基因在体内外对人骨肉瘤细胞生长抑制效应及其分子机制。将Ad-IL-24重组腺病毒感染MG-63细胞,用荧光显微镜、RT-PCR法检测IL-24在MG-63细胞中的转录和表达;MTT法、流式细胞技术和Hoechst染色法检测IL-24基因的表达对MG-63细胞的生长抑制和凋亡效应;半定量RT-PCR法检测IL-24基因的表达对MG-63细胞中的bcl-2、bax、caspase-3相关基因表达的影响。用Ad-IL-24重组腺病毒在MG-63骨肉瘤荷瘤裸鼠的瘤体内进行注射治疗,观察肿瘤生长变化,15d后处死裸鼠,摘除瘤体,称瘤重。并通过免疫组化法检测Bcl-2、Bax、Caspase-3等与细胞凋亡相关因子的表达。结果表明Ad-IL-24重组腺病毒感染MG-63细胞后,能明显抑制MG-63细胞增殖,并能通过上调细胞中bax、caspase-3和下调bcl-2基因表达,诱导细胞凋亡,呈现出典型细胞凋亡形态学变化。Ad-IL-24重组腺病毒瘤内注射MG-63裸鼠荷瘤骨肉瘤移植瘤后,能显著抑制肿瘤生长,瘤重的抑制率可达52%,免疫组化结果显示Ad-IL-24重组腺病毒能明显上调与细胞...     

Ad-IL-24对SGC-7901胃癌细胞生长抑制的体外实验

旨在研究携带人IL-24基因的腺病毒表达载体(Ad-IL-24)对SGC-7901人胃癌细胞的生长抑制作用并分析其分子机制。以不同MOI(感染复数)的Ad空载体腺病毒感染SGC-7901人胃癌细胞,筛选出最佳感染剂量;Ad-IL-24以最佳感染剂量感染SGC-7901胃癌细胞,RT-PCR法和Western blotting法检测腺病毒介导的IL-24基因在SGC-7901胃癌细胞中的转录;MTT法检测Ad-IL-24对SGC-7901胃癌细胞的生长抑制作用,流式细胞仪检测其诱导SGC-7901人胃癌细胞凋亡和细胞周期改变的效应,Hoechst33258染色荧光显微镜检测其诱导胃癌细胞凋亡的核形态改变;RT-PCR半定量法进一步检测SGC-7901胃癌细胞中凋亡相关基因的转录。结果显示,100MOI为感染SGC-7901胃癌细胞的腺病毒最佳感染剂量;Ad-IL-24能成功介导IL-24基因在SGC-7901胃癌细胞中转录性表达;Ad-IL-24感染SGC-7901胃癌细胞后,能明显抑制胃癌细胞生长和诱导凋亡;Ad-IL-24能显著上调SGC-7901胃癌细胞中bax、caspase-3和p53的表达和下调bc...     

怀化医学高等专科学校医学形态学实验中心

目的:探讨抑癌基因p16对肝癌细胞生长的抑制作用及其机制。方法:将p16 cDNA亚克隆至pcDNA3.1真核表达载体上,并经脂质体介导转染至人肝癌细胞株SMMC-7721。用MTT法和Western blot分析转染细胞的生长情况。结果:成功构建重组表达质粒pcDNA3.1-p16,转染pcDNA3.1-p16的SMMC-7721细胞生长速度受到明显抑制;转染后有外源p16蛋白的表达,且伴随Bax上调,Bcl-2和cIAP2的下调。结论:重组pcDNA3.1-p16质粒能在人肝癌细胞SMMC-7721内表达,且能抑制SMMC-7721的生长,其机理与诱导肿瘤细胞凋亡相关。     

抑癌基因p16对人肝癌细胞生长抑制的机制研究

目的：探讨抑癌基因p16对肝癌细胞生长的抑制作用及其机制。方法：将p16cDNA亚克隆至pcDNA3．1真核表达载体上,并经脂质体介导转染至人肝癌细胞株SMMC-7721：用MTT法和Western blot分析转染细胞的生长情况。结果：成功构建重组表达质粒pcDNA3．1-p16,转染pcDNA3．1-p16的SMMC-7721细胞生长速度受到明显抑制;转染后有外源p16蛋白的表达,且伴随Bax上调,Bcl-2和cIAP2的下调。结论：重组pcDNA3．1-p16质粒能在人肝癌细胞SMMC-7721内表达,且能抑制SMMC-7721的生长,其机理与诱导肿瘤细胞凋亡相关。     

腺病毒介导hIL-24抑制裸鼠肝癌荷瘤生长及其机制研究

为了研究腺病毒hIL-24抑制SMMC-7721肝癌细胞裸鼠荷瘤的生长抑制及其作用机制,构建了重组腺病毒载体pAdeasy-1-pTrack-CMV-hIL-24(Ad-hIL-24),经PacI线性化后转染QBI-293A细胞,多轮感染后收获高效价腺病毒重组病毒子。用SMMC-7721肝癌细胞使16只裸鼠致瘤,然后随机NS分成干预组、5-Fu组、Ad组和Ad-hIL-24组,进行抗肿瘤试验。四组均使用瘤体内注射干预用药,100μL/只NS组、Ad组(107pfu)和Ad-hIL-24组(107pfu)隔日一次,共注射5次;5-Fu组20μg/kg,连续注射5d。用药前、用药后1周和2周分别测皮下瘤体的长径(L)、短径(W),计算出瘤体体积,治疗开始后第15天,将裸鼠脱颈处死,摘取瘤体称重,计算出抑瘤率。显微镜观察细胞生长形态、免疫组化法测caspase3蛋白表达、P53及P27核内抑癌基因表达、CD34染色标记测定的MVD及VEGF蛋白表达。与NS组比较,Ad-hIL-24组与5-Fu组的抑瘤率分别为68.52%(P<0.01)和65.64%(P<0.01);镜下Ad-hIL-24组肿瘤组织的caspase3蛋白表达细胞数较其它3组呈显著性升高(P<0.01),P27核内抑癌基因表达细胞数也较NS组明显增高(P<0.01),CD34染色标记测定的CD34及VEGF较NS组和Ad组明显减少(P<0.001),P53未见明显变化。结论Ad-hIL-24可以显著抑制裸鼠SMMC-7721荷瘤的生长,其机制可能通过激活caspase途径、上调P27抑癌基因表达、抑制血管形成等多途径发挥抑瘤作用。     

Ad-IL-24对人胶质瘤细胞生长抑制效应的体外实验

研究携带人白介素24(IL-24)的腺病毒表达载体(Ad-IL-24)对人U251胶质瘤细胞生长的影响和抗肿瘤分子机制。将不同MOI Ad-IL-24感染U251人胶质瘤细胞后, MTT法检测Ad-IL-24对U251细胞生长的抑制作用, 流式细胞仪和Hochest 染色法检测细胞的凋亡率。RT-PCR检测bcl-2、bax、ICE、C-myc、HIF-1a和p53等基因的转录表达水平, Western blotting检测Cleaved Caspase-3的表达。结果表明100 MOI Ad-IL-24感染U251细胞后能明显抑制细胞生长, 并能明显诱导细胞凋亡, 感染72 h后细胞凋亡率可达42%, 感染4 d后细胞生长抑制率可达50%。RT-PCR检测发现Ad-IL-24能引起与细胞凋亡和血管形成相关基因bax/bcl-2、ICE、C-myc、p53的上调和HIF-1a的下调, 并促进Caspase-3的活化。本研究结果显示Ad-IL-24能明显抑制人胶质瘤细胞U251生长和诱导细胞凋亡, 其抗肿瘤机制可能与通过bax/ bcl-2、ICE、c-myc、p53的上调和HIF-1a的下调, 进而导致Caspase-3的活化而诱导肿瘤细胞发生凋亡有关。     

携带TSLC1基因的双靶向溶瘤腺病毒联合阿霉素对SMMC-7721肝癌细胞的杀伤作用

研究携带TSLC1基因的溶瘤腺病毒(Ad.sp-E1A(24)-TSLC1)联合化疗药物阿霉素(adriamycin,ADM)对SMMC-7721肝癌细胞的体外杀伤作用。实时定量PCR检测TSLC1在不同肝细胞中的表达情况;用荧光显微镜观察阿霉素、Ad.sp-E1A(24)-TSLC1单独作用和两者联合作用的细胞形态学的变化;采用MTT法、结晶紫染色、Hoechst33342染色检测各处理组细胞的存活率和凋亡水平情况;通过Western blot检测TSLC1和E1A蛋白水平的表达。结果表明,联合应用Ad.sp-E1A(24)-TSLC1和阿霉素的细胞凋亡现象比单独作用的效果显著,表明阿霉素能够增强携带TSLC1基因的溶瘤腺病毒对肝癌细胞SMMC-7721的杀伤作用,为肝癌治疗的临床应用奠定一定基础。     

人IL-17F对裸鼠人肝癌移植瘤生长的影响

利用RT-PCR方法从PHA活化的人外周血单个核细胞(PBMCs)中克隆hIL-17F基因,亚克隆至逆转录病毒载体pSIV-1,与辅助病毒载体pHIT456和pHIT60脂质体法共转染293T包装细胞,获得的成熟重组逆转录病毒(RV-hIL-17F)再感染SMMC-7721人肝癌细胞,并经G418筛选建立hIL-17F转基因肝癌细胞。PCR、RT-PCR和Westernblot结果表明hIL-17F基因在肝癌细胞中能成功整合、转录和表达。MTT和FCM结果表明hIL-17F不能改变SMMC-7721肝癌细胞的增殖活力和细胞周期,但ELISA结果表明其能明显下调肝癌细胞IL-6、IL-8和VEGF的表达。转基因肝癌细胞rhIL-17F表达上清具有抑制ECV304人脐静脉内皮细胞生长的作用。裸鼠皮下成瘤试验结果表明hIL-17F转基因肝癌细胞裸鼠致瘤能力明显减弱,VEGF和CD34表达降低,血管形成显著减少。hIL-17F可通过减少肿瘤血管形成显著抑制裸鼠人肝癌移植瘤的生长,为其进一步开展肿瘤血管靶向基因治疗和开发抗血管新药提供了一定的实验依据。     

人hIL-24Δ103重组腺病毒感染诱导A549细胞凋亡

白细胞介素24（interleukin 24，IL-24）是近年来新发现的1个IL-10家族细胞因子，具有明显的抗肿瘤活性．为了研究开发高活性、低分子量的IL-24,并探讨其用于肿瘤靶向治疗的可能性，本研究在前期基础上,进一步构建并制备了缺失N端103个氨基酸残基的IL-24（hIL-24Δ103）重组腺病毒，并观察了其对A549细胞生长增殖和凋亡的影响．首先,采用PCR技术扩增IL-24第104位至第206位氨基酸区域的编码序列，制备hIL-24Δ103重组腺病毒．用Ad-hIL-24Δ103重组腺病毒感染肺癌A549细胞. MTT分析结果表明，Ad-hIL-24Δ103感染显著抑制了A549细胞的生长．Hoechst 33258染色和流式细胞仪分析结果表明，Ad-hIL 24Δ103感染导致细胞凋亡．Western 印迹分析结果表明，Ad-hIL-24Δ103感染导致了PKR和eIF-2α蛋白的表达上调与磷酸化激活，提示PKR和eIF-2α参与了hIL-24Δ103导致的细胞生长抑制和细胞凋亡过程的调节．关键词 人白介素24；腺病毒；细胞增殖；细胞凋亡     

一种新的重组腺病毒的构建及其对人肿瘤细胞的影响

腺病毒E1A基因诱导细胞凋亡．E1B19K基因及E1B55K基因抑制细胞凋亡,前者被克隆到腺病毒转移载体pCA13的HCMVIE启动子下游．构建成转移载体pCAE1A。采用lipofectin法将PCAE1A和含腺病毒基因组（E1、E3区缺失）的质粒pBHG11共转染293细胞,7～10d后得到重组病毒v5Ad4。用v5Ad4感染人肺腺癌细胞系A549,结果表明v5Ad4有明显杀伤和裂解肿瘤细胞功能。在人胚肺正常二倍体细胞中,v5Ad4没有表现出可见的细胞毒效应。     

人溶菌酶基因的合成和克隆

用固相亚磷酰胺法合成了人溶菌酶的全基因,全长为409bp,它包括了编码人溶菌酶的结梅基因,起始密码于ATG,终止密码子TAA、TGA,以及两端的BamHI和SphI的识别顺序。整个基因分成24个寡聚核苷酸片段进行合成,每个片段长度分别为26至38个核苷酸．然后用两种方法酶促连接成完整的人溶菌酶基因。基因克隆到M13载体上。用点杂交和限制酶酶切分析确定阳性克隆株。用双脱氧链终止法进行序列分析,证实所合成的人溶菌酶基因序列与设计的完全一致。     

Targeting gene-virotherapy of cancer and its prosperity

Gene and viral therapies for cancer have shown some therapeutic effects, but there has been a lack of real breakthrough. To achieve the goal of complete elimination of tumor xenograft in animal models, we have developed a new strategy called Targeting Gene-Virotherapy of Cancer, which aims to combine the advantages of both gene therapy and virotherapy. This new strategy has produced stronger anti-tumor effects than either gene or viral therapy alone. A tumorspecific replicative adenovirus vector, designated as ZD55, was constructed by deletion of the 55kDa E1B region of adenovirus. The resulting viral construct not only retains a similar function to ONYX-015 by specifically targeting p53 negative tumors, but also allows for the insertion of various therapeutic genes to form appropriate ZD55 derivatives due to the newly introduced cloning site, a task not feasible with the original ONYX-015 virus. We showed that the anti-tumor effect of one such derivative, ZD55-IL-24, is at least 100 times more potent than that of either ZD55 virotherapy or Ad-IL-24 gene therapy. Nevertheless, complete elimination of tumor mass by the use of ZD55-1L-24 was only observed in some but not all mice, indicating that one therapeutic gene was not sufficient to ＂cure＂ these mice. When genes with complementary or synergetic effects were separately cloned into the ZD55 vector and used in combination （designated as the Dual Gene Therapy strategy）, much better results were obtained; and it was possible to achieve complete elimination of all the xenograft tumor masses in all mice if two suitable genes were chosen. More comprehensive studies based on this new strategy will likely lead to a protocol for clinical trial. Finally, the concept of Double Controlled Targeting Virus-Dual Gene Therapy for cancer treatment, and the implication of the recent progress in cancer stem cells are also discussed.     

A novel gain-of-function mutation of the integrin alpha2 VWFA domain.

Integrin alpha2beta1 is the major receptor for collagens in human tissues, being involved in cell adhesion and the control of collagen and collagenase gene expression. The collagen binding site of alpha2beta1 has been localized to the alpha2 von Willebrand Factor type A (VWFA) domain (A-domain or I-domain) and the residues responsible for the interaction with collagen have been mapped. We report a study of alpha2 VWFA domain in which residue E318, which lies outside the collagen binding site, is mutated to tryptophan, showing that this is a gain-of-function mutation. Recombinant alpha2-E318W VWFA domain showed elevated and specific binding to collagen I compared with the wild-type. Side chain hydrophobicity was important for the gain-of-function as elevated binding was seen with E318I and E318Y, but not with E318R. The E318W mutation had additional effects on VWFA domain properties as alpha2-E318W VWFA domain differed from the wild-type in its cation preferences for ligand binding and in binding to monoclonal antibody JA203, which bound at a site distal to E318. The gain-of-function effect was not restricted to binding to collagen I as alpha2-E318W also showed elevated binding to collagen IV, collagen I C-propeptide, laminin and E-cadherin. Binding to these ligands was inhibited by collagen peptide containing the GFOGER motif, indicating that these bound to the VWFA domain by a similar mechanism to collagen I. These data indicate that residue E318 plays a novel and important role in modulating alpha2 VWFA domain--ligand binding and may be involved in the conformational changes associated with its regulation.     

The Protective Effect of Intrasplenic Transplantation of Ad-IL-18BP/IL-4 Gene-Modified Fetal Hepatocytes on ConA-Induced Hepatitis in Mice

Background

Concanavalin A (ConA)-induced hepatitis is an experimental murine model mirroring the pathology of human autoimmune hepatitis.

Aim

To investigate the effects of intrasplenically transplanted fetal hepatocytes (BNL.CL2) transfected with recombinant adenovirus vector expressing the IL-18 binding protein (IL-18BP) and IL-4 fusion protein on ConA-induced hepatitis in mice.

Methods

Ad-IL-18BP/IL-4 was used to infect BNL.CL2 cells. IL-4 and IL-18BP fusion protein expression were detected by ELISA and Western blotting. BNL.CL2 cells infected with Ad-IL-18BP/IL-4 were intrasplenically transplanted into mice. After 10 days, mice were injected with ConA (15 mg/kg), and sacrificed 18 hours later. Liver injury was assessed by serum transaminase and liver histology. TNF-α, IL-18, IL-4, IL-10, IL-12p70 and monocyte-chemoattracting protein (MCP)-1 levels in serum and liver homogenates were detected by ELISA. Signaling molecules in liver homogenates were analyzed by Western blotting.

Results

Ad-IL-18BP/IL-4 effectively expressed the IL-18BP/IL-4 fusion protein for more than 14 days in BNL.CL12 cells. Treatment of mice with Ad-IL-18BP/IL-4-BNL.CL2 before ConA injection significantly reduced the elevated plasma levels of transaminases compared with ConA control groups. TNF-α, IL-18, IL-12p70 and MCP-1 levels in serum and liver homogenates from mice transplanted with Ad-IL-18BP/IL-4-BNL.CL2 were lower and IL-4 and IL-10 levels were higher than control groups. Phosphorylation levels of NF-κB p65, AKT, p38 and JNK1/2 in liver homogenates were markedly suppressed by Ad-IL-18BP/IL-4.

Conclusions

Ad-IL-18BP/IL-4 was effectively transfected into mouse BNL.CL2 cells. Intrasplenic transplantation of Ad-IL-18BP/IL-4-BNL.CL12 cells alleviated the severity of inflammation in ConA-induced experimental hepatitis and provides a useful basis for the targeted gene therapy of liver disease.     

Mutation of alanine 24 to serine in subunit c of the Escherichia coli F1F0-ATP synthase reduces reactivity of aspartyl 61 with dicyclohexylcarbodiimide.

Dicyclohexylcarbodiimide (DCCD) inhibits the activity of the F1F0-H+ ATP synthase of Escherichia coli by reacting with aspartyl 61 in subunit c of the FO sector to form a stable N-acylurea. The segment of chromosomal DNA which codes the subunits of the FO was cloned from four independently isolated DCCD-resistant mutants, and the sequence of the subunit c gene (uncE) was determined. An Ala24 to serine (A24S) substitution was found in the subunit c gene of each mutant. The A24S uncE gene was cloned into the BamHI site of a mutant derivative of plasmid pBR322. The A24S subunit c conferred DCCD resistance to a variety of recipient E. coli strains when it was overexpressed from this plasmid. A 7-base pair deletion beginning at position 132 of the plasmid vector was responsible for the observed overexpression. Hoppe et al. (Hoppe, J., Schairer, H. U., and Sebald, W. (1980) Eur. J. Biochem. 112, 17-24) had previously shown that mutation of subunit c Ile28 to threonine or valine resulted in DCCD resistance. The DCCD sensitivities of the membrane ATPase of these mutants and the A24S mutant were compared. DCCD sensitivity decreased in the order: wild-type much greater than I27V greater than I28T = A24S. The venturicidin sensitivities of wild-type and mutant membranes were also examined. The membrane ATPase of the I28T and I28V mutants was venturicidin resistant whereas the A24S substitution resulted in a hypersensitivity to inhibition by venturicidin. These results support a model in which subunit c folds in the membrane like a hairpin, where the region of residues 24-28 in transmembrane helix-1 is close to that of aspartyl 61 in transmembrane helix-2.     

pAM401-based shuttle vectors that enable overexpression of promoterless genes and one-step purification of tag fusion proteins directly from Enterococcus faecalis

Two novel Enterococcus faecalis-Escherichia coli shuttle vectors that utilize the promoter and ribosome binding site of bacA on the E. faecalis plasmid pPD1 were constructed. The vectors were named pMGS100 and pMGS101. pMGS100 was designed to overexpress cloned genes in E. coli and E. faecalis and encodes the bacA promoter followed by a cloning site and stop codon. pMGS101 was designed for the overexpression and purification of a cloned protein fused to a Strep-tag consisting of 9 amino acids at the carboxyl terminus. The Strep-tag provides the cloned protein with an affinity to immobilized streptavidin that facilitates protein purification. We cloned a promoterless beta-galactosidase gene from E. coli and cloned the traA gene of the E. faecalis plasmid pAD1 into the vectors to test gene expression and protein purification, respectively. beta-Galactosidase was expressed in E. coli and E. faecalis at levels of 10(3) and 10 Miller units, respectively. By cloning the pAD1 traA into pMGS101, the protein could be purified directly from a crude lysate of E. faecalis or E. coli with an immobilized streptavidin matrix by one-step affinity chromatography. The ability of TraA to bind DNA was demonstrated by the DNA-associated protein tag affinity chromatography method using lysates prepared from both E. coli and E. faecalis that overexpress TraA. The results demonstrated the usefulness of the vectors for the overexpression and cis/trans analysis of regulatory genes, purification and copurification of proteins from E. faecalis, DNA binding analysis, determination of translation initiation site, and other applications that require proteins purified from E. faecalis.